Conducted in 148 centers in Canada, New Zealand, and the United States between September 1997 and July 2001, SCD-HeFT involved a total of 2521 patients with dilated cardiomyopathy, with or without ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback